Rational Design of Cancer-Targeted BSA Protein Nanoparticles as Radiosensitizer to Overcome Cancer Radioresistance
Source abstract
Abstract
Radiotherapy displays curative potential for cervical cancer management, but radioresistance occurs during long-term therapy. To overcome this limitation, tumor-targeted nanotechnology has been proposed to enhance the radiosensitivity of solid tumors. Herein, we used biocompatible bovine serum albumin nanoparticles (BSANPs) as carriers of organic selenocompound (PSeD) with folate (FA) as the targeting ligand to fabricate a cancer-targeted nanosystem. The combination of PSeD and BSANPs endowed the nanosystem with higher light absorption and reactive oxygen species (ROS) generation owing to their properties of surface plasmon resonance (SPR) effect, heavy metal effect, high refractive index and nanoparticulate interfacial effect. The combined treatment drastically increased the ROS overproduction, VEGF/VEGFR2 inactivation and inhibition of XRCC-1-mediated repair of DNA damage, thus triggering G2/M phase arrest and apoptosis. Taken together, our findings demonstrate the utility of FA-BSANPs as a promising radiosensitizer to improve cancer radiotherapy.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Nanoplatforms for cancer theranostics · Nanoparticle-Based Drug Delivery · Selenium in Biological Systems
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Chemistry, Jinan University, Guangzhou 510632, China
Funding
National Natural Science Foundation of China · Ministry of Education of the People's Republic of China · Ministry of Science and Technology of the People's Republic of China · China Postdoctoral Science Foundation · Natural Science Foundation of Guangdong Province
References (52)
Show source-provided references
1. Lord C. J. · Nature · 2012 · 481 · 28710.1038/nature10760 ↗
2. Fan W. P. · J. Am. Chem. Soc. · 2013 · 135 · 649410.1021/ja312225b ↗
3. Pan Y. · Oncogene · 2013 · 32 · 275610.1038/onc.2012.294 ↗
4. Beskow C. · Br. J. Cancer · 2009 · 101 · 81610.1038/sj.bjc.6605201 ↗
5. Wang M. · Cancer Res. · 2011 · 71 · 626110.1158/0008-5472.CAN-11-0213 ↗
6. Gu J. L. · J. Phys. Chem. Lett. · 2010 · 1 · 344610.1021/jz101483u ↗
7. Werner M. E. · ACS Nano · 2011 · 5 · 899010.1021/nn203165z ↗
8. Corde S. · Cancer Res. · 2003 · 63 · 3221
9. Sinha R. · Curr. Cancer Drug Targets · 2004 · 4 · 1310.2174/1568009043481614 ↗
10. Li S. · Mol. Cancer Ther. · 2007 · 6 · 103110.1158/1535-7163.MCT-06-0643 ↗
11. Chen T. · Chem.-Biol. Interact. · 2009 · 180 · 5410.1016/j.cbi.2008.12.010 ↗
12. Chen T. · J. Agric. Food Chem. · 2008 · 56 · 1057410.1021/jf802125t ↗
13. Luo Y. · Chem. Pharm. Bull. · 2013 · 59 · 122710.1248/cpb.59.1227 ↗
14. Luo Y. · MedChemComm · 2012 · 3 · 114310.1039/c2md20041d ↗
15. Liu X. · Adv. Healthcare Mater. · 2013 · 2 · 95210.1002/adhm.201200388 ↗
16. Barrow S. J. · Nano Today · 2013 · 8138
17. Luo Z. · ACS Nano · 2013 · 7 · 1027110.1021/nn404676w ↗
18. Kakuta T. · Adv. Mater. · 2013 · 25 · 284910.1002/adma.201205321 ↗
19. Peng L. · Nano Lett. · 2013 · 13 · 215110.1021/nl400600x ↗
20. Caracciolo G. · ACS Appl. Mater. Interfaces · 2013 · 5 · 1317110.1021/am404171h ↗
21. Zhao M. X. · Nano Today · 2013 · 8 · 1110.1016/j.nantod.2012.12.003 ↗
22. Taratula O. · J. Controlled Release · 2013 · 171 · 34910.1016/j.jconrel.2013.04.018 ↗
23. Park S. · Biomaterials · 2013 · 34 · 59810.1016/j.biomaterials.2012.10.004 ↗
24. Kratz F. · J. Controlled Release · 2008 · 132 · 17110.1016/j.jconrel.2008.05.010 ↗
25. Heukers R. · Biomaterials · 2014 · 35 · 60110.1016/j.biomaterials.2013.10.001 ↗
26. Zhang S. F. · Biomaterials · 2010 · 31 · 95210.1016/j.biomaterials.2009.10.011 ↗
27. Mohanta V. · J. Phys. Chem. C · 2012 · 116 · 533310.1021/jp209479n ↗
28. Xie L. L. · J. Mater. Chem. · 2012 · 22 · 605310.1039/c2jm16831f ↗
29. Bae S. · Biomaterials · 2012 · 33 · 153610.1016/j.biomaterials.2011.10.050 ↗
30. Destito G. · Chem. Biol. · 2007 · 14 · 115210.1016/j.chembiol.2007.08.015 ↗
31. Harada H. · Oncogene · 2007 · 26 · 750810.1038/sj.onc.1210556 ↗
32. Iftner T. · EMBO J. · 2002 · 21 · 474110.1093/emboj/cdf443 ↗
33. Franken N. A. · Nat. Protoc. · 2006 · 1 · 231510.1038/nprot.2006.339 ↗
34. Chen T. F. · Biomed. Pharmacother. · 2009 · 63 · 10510.1016/j.biopha.2008.03.009 ↗
35. Huang Y. · Biomaterials · 2013 · 34 · 710610.1016/j.biomaterials.2013.04.067 ↗
36. Chen T. F. · Int. J. Biochem. Cell Biol. · 2009 · 41 · 66610.1016/j.biocel.2008.07.014 ↗
37. Nagata S. · Cell. · 1997 · 88 · 35510.1016/S0092-8674(00)81874-7 ↗
38. Thorburn A. · Cell Signalling · 2004 · 16 · 13910.1016/j.cellsig.2003.08.007 ↗
39. Aggarwal B. B. · Nat. Rev. Immunol. · 2003 · 3 · 74510.1038/nri1184 ↗
40. Hengartner M. O. · Nature · 2000 · 407 · 77010.1038/35037710 ↗
41. Tay C. Y. · ACS Appl. Mater. Interfaces · 2014 · 6 · 624810.1021/am501266a ↗
42. Tsukamoto H. · BMC Cancer · 2008 · 8 · 110.1186/1471-2407-8-74 ↗
43. Kim J. G. · PloS one · 2014 · 9 · 1
44. Pelicano H. · Drug Resist. Updates · 2004 · 7 · 9710.1016/j.drup.2004.01.004 ↗
45. Zhang X. D. · Adv. Mater. · 2014 · 26 · 456510.1002/adma.201400866 ↗
46. Zhang X. D. · Adv. Healthcare Mater. · 2014 · 3 · 13310.1002/adhm.201300189 ↗
47. Horie M. · Chem. Res. Toxicol. · 2013 · 25 · 60510.1021/tx200470e ↗
48. Setyawati M. I. · Biomaterials · 2013 · 35 · 670710.1016/j.biomaterials.2014.05.007 ↗
49. Raingeaud J. · J. Biol. Chem. · 1995 · 270 · 742010.1074/jbc.270.13.7420 ↗
50. Nam S. Y. · J. Biol. Chem. · 2010 · 285 · 3115710.1074/jbc.M110.122044 ↗
51. Xia S. · Cancer Biother. Radiopharm. · 2010 · 25 · 317
52. Fritz G. · Int. J. Radiat. Biol. · 2003 · 79 · 60110.1080/09553000310001609233 ↗